<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976170</url>
  </required_header>
  <id_info>
    <org_study_id>GC-002US</org_study_id>
    <nct_id>NCT00976170</nct_id>
  </id_info>
  <brief_title>Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)</brief_title>
  <official_title>A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33 in Combination With Sorafenib (Nexavar®) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (HCC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination&#xD;
      in patients with advanced or metastatic liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I open-label dose escalation study of GC33 in combination with Sorafenib in&#xD;
      patients with advanced or metastatic HCC. This study is designed to evaluate safety,&#xD;
      tolerability, pharmacokinetics, and efficacy. Enrollment will proceed until a maximum&#xD;
      tolerated dose (MTD) and a recommended Phase II dose has been established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity evaluation in accordance with CTCAE v3.0</measure>
    <time_frame>Continuous</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity and maximum tolerated dose</measure>
    <time_frame>Continuous</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>RECIST criteria (version 1.0) for response evaluation by CT/MRI in target and non-target lesions of HCC</measure>
    <time_frame>every 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat-dose pharmacokinetic behavior of GC33 and Sorafenib</measure>
    <time_frame>Continuous</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC33(RO5137382)</intervention_name>
    <description>IV administration at 6 escalating dose levels.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Oral administration at 400mg twice daily or 400mg once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written Institutional Review Board/Ethical Committee approved informed consent&#xD;
             form.&#xD;
&#xD;
          -  Male or female ≥18 years old.&#xD;
&#xD;
          -  Life expectancy ≥3 months.&#xD;
&#xD;
          -  ECOG Performance Status of 0-1.&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma.&#xD;
&#xD;
          -  Not a candidate for curative treatments.&#xD;
&#xD;
          -  Child-Pugh A&#xD;
&#xD;
          -  Hematological, Biochemical and Organ Function:&#xD;
&#xD;
               -  AST (SGOT): ≤5.0 × ULN,&#xD;
&#xD;
               -  ALT (SGPT): ≤5.0 × ULN,&#xD;
&#xD;
               -  Total Bilirubin: ≤1.5mg/dL,&#xD;
&#xD;
               -  Platelets: ≥100,000/μL,&#xD;
&#xD;
               -  Absolute Neutrophil Count: ≥1,500/μL,&#xD;
&#xD;
               -  Serum creatinine: ≤2.0 × ULN,&#xD;
&#xD;
               -  PT-INR: ≤2.0&#xD;
&#xD;
          -  Ability to provide a tumor tissue sample either by:&#xD;
&#xD;
               -  A formalin fixed paraffin embedded block sample within 12 months prior to&#xD;
                  informed consent for HCC diagnosis&#xD;
&#xD;
               -  Undergo a biopsy to confirm HCC diagnosis&#xD;
&#xD;
          -  Measurable disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh B or C&#xD;
&#xD;
          -  Patient who have taken Sorafenib previously.&#xD;
&#xD;
          -  Difficulty or inability to swallow pills.&#xD;
&#xD;
          -  Pregnant or lactating women or women of child-bearing potential and men of&#xD;
             childbearing potential not willing to use effective means of contraception.&#xD;
&#xD;
          -  Patients known to be positive for Human immunodeficiency virus infection.&#xD;
&#xD;
          -  Active infectious diseases requiring treatment except for hepatitis B and C.&#xD;
&#xD;
          -  Other malignancies within the last 5 years.&#xD;
&#xD;
          -  History of transplantation (organ, bone marrow transplantation, Peripheral blood stem&#xD;
             cell transplantation, etc.).&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements..&#xD;
&#xD;
          -  Patients with known brain metastases or other central nervous system&#xD;
             disease/disorders.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure &gt;150 mmhg or diastolic&#xD;
             blood pressure &gt;90 mmHg, despite optimal medical management.&#xD;
&#xD;
          -  Non-tumor related thrombolic or embolic events such as a cerebrovascular accident&#xD;
             including transient ischemic attacks within the past 6 months.&#xD;
&#xD;
          -  Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 3, any other hemorrhage/bleeding&#xD;
             event ≥ CTCAE Grade 4 within 4 weeks of first dose of study drug.&#xD;
&#xD;
          -  Serious non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Patients who received major surgery, local therapy for HCC, chemotherapy,&#xD;
             radiotherapy, hormone-therapy, immunotherapy, or another investigational drug within 4&#xD;
             weeks prior to Day 1(6 weeks for nitrosoureas, mitomycin, and bevacizumab; 1 week for&#xD;
             tumor biopsy).&#xD;
&#xD;
          -  Patients who received the following treatments within 2 weeks prior to Day 1:&#xD;
&#xD;
               -  Anticoagulant or thrombolytic agents for therapeutic purposes,&#xD;
&#xD;
               -  Systemic anti-viral therapy for hepatitis C and Interferon therapy for hepatitis&#xD;
                  B,&#xD;
&#xD;
               -  Blood transfusion including all blood products&#xD;
&#xD;
          -  Known history of hypersensitivity to similar agents.&#xD;
&#xD;
          -  Patients receiving any medications or substances that are inducers of CYP3A4 are&#xD;
             ineligible: rifampin, St. John's wort, phenytoin, carbamazepine, phenobarbital and&#xD;
             dexamethasone.&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol requirements and/or follow-up procedures;&#xD;
             those conditions should be discussed with the patient before trial entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan Univercity Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced or metastatic HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

